COVID-19 Vaccine Reduces Preeclampsia Risk During Pregnancy | Healio

New data suggest a strong link between COVID-19 vaccination during pregnancy and a reduced risk of preeclampsia, a serious blood pressure disorder that can occur during and after pregnancy. The findings, published in eClinicalMedicine, add to a growing body of evidence supporting the safety and benefits of prenatal COVID-19 vaccination and highlight the potential for vaccination to protect against severe pregnancy complications.

The Interplay of Infection and Immunity

The study, led by researchers at Northwestern University Feinberg School of Medicine and involving over 6,500 pregnant women across 18 countries, examined the impact of vaccination status and SARS-CoV-2 infection on preeclampsia rates. Researchers found that unvaccinated pregnant women who contracted COVID-19 faced a significantly elevated risk – up to 78% higher – of developing preeclampsia compared to those who were not infected. Vaccination, particularly with a booster dose, appeared to mitigate this risk.

“These results support the importance of strengthening COVID vaccination programs during pregnancy, emphasizing boosters and ensuring that pregnant people across the world have equitable access to the vaccine,” said study co-author Jagjit S. Teji, MD, in a press release. “We offer evidence from the first large study suggesting that COVID vaccination may protect against one of the most serious pregnancy complications.” Healio provides further details on the study’s findings.

Understanding Preeclampsia and its Risks

Preeclampsia is characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It typically develops after 20 weeks of pregnancy and can lead to serious complications for both mother and baby, including preterm birth, seizures, stroke, and even death. While the exact cause of preeclampsia remains unknown, it is believed to involve a combination of factors, including genetic predisposition, immune dysfunction, and placental abnormalities. The Mayo Clinic offers a comprehensive overview of preeclampsia, its symptoms, and potential complications.

Study Details and Limitations

The INTERCOVID Consortium cohort study analyzed data collected between 2020 and 2022. The cohort comprised 33.2% of women diagnosed with COVID-19 and 57.5% who were unvaccinated. Among vaccinated participants, 64.7% received mRNA vaccines, and 30.6% received an initial vaccine plus a booster, with 66.6% of those boosters being mRNA-based.

The researchers reported that vaccination reduced the risk for preeclampsia (adjusted OR = 0.85. 95% CI, 0.65-1.1), and this protective effect was even more pronounced with a booster dose (adjusted OR = 0.67; 95% CI, 0.45-0.99). Notably, vaccination with a booster lowered preeclampsia risk by 58% (adjusted OR = 0.42; 95% CI, 0.2-0.87) among women with pre-existing conditions like diabetes, thyroid disorders, or hypertension.

It’s important to note the study’s observational nature. As the authors acknowledge, this introduces the potential for selection bias – women who chose to get vaccinated may have differed in other ways from those who did not, potentially influencing the results. Residual confounding and the risk of overstating results due to reduced statistical power in certain analyses are also acknowledged limitations. The study demonstrates association, not causation; it cannot definitively prove that vaccination *causes* the reduction in preeclampsia risk, only that a relationship exists.

Beyond Preeclampsia: Broader Protective Effects

The benefits of COVID-19 vaccination during pregnancy extended beyond preeclampsia. The study also found that vaccination was associated with lower risks of preterm delivery, maternal morbidity and mortality, and severe perinatal morbidity and mortality. The protective effects were again amplified with booster doses, reducing the risk of preterm birth by 33%, maternal morbidity and mortality by 32%, and severe perinatal morbidity and mortality by 29%.

Implications for Public Health and Clinical Practice

These findings reinforce current recommendations from public health organizations, including the Centers for Disease Control and Prevention (CDC), which strongly recommend COVID-19 vaccination for all pregnant people. The CDC emphasizes that COVID-19 vaccination is safe and effective during pregnancy and can protect both the mother and the baby from severe illness.

The study also opens avenues for further research into the underlying mechanisms by which COVID-19 vaccination may protect against preeclampsia. Dr. Teji suggests that understanding these pathways could shed light on the etiology of preeclampsia itself, potentially leading to new prevention and treatment strategies.

What’s Next: Ongoing Research and Surveillance

Researchers are continuing to investigate the long-term effects of COVID-19 vaccination during pregnancy and to monitor for any potential safety concerns. Ongoing surveillance efforts are crucial for identifying any rare adverse events and for assessing the effectiveness of vaccination against emerging variants. Further clinical trials are needed to confirm these findings and to explore the potential benefits of vaccination at different stages of pregnancy. The World Health Organization (WHO) continues to monitor the global COVID-19 situation and provide updated guidance on vaccination strategies.

The current evidence strongly suggests that COVID-19 vaccination is a safe and effective way to protect pregnant women and their babies from the serious complications of COVID-19, and potentially from preeclampsia as well. Pregnant individuals should discuss vaccination with their healthcare provider to develop an informed decision that is right for them.